Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by stock analysts at Barclays from $329.00 to $341.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an "overweight" rating on the biotechnology company's stock. Barclays's price target indicates a potential upside of 24.19% from the stock's current price.
A number of other analysts have also commented on ASND. KeyCorp set a $330.00 price objective on Ascendis Pharma A/S in a research report on Friday. UBS Group boosted their price objective on Ascendis Pharma A/S from $269.00 to $315.00 and gave the stock a "buy" rating in a report on Friday. Citigroup cut their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a "buy" rating on the stock in a research report on Monday, October 26th. Stifel Nicolaus reduced their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a "buy" rating on the stock in a research note on Monday, August 31st. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average price target of $314.10.
Read Our Latest Stock Analysis on ASND
Ascendis Pharma A/S Trading Down 0.3%
NASDAQ:ASND traded down $0.81 during trading hours on Monday, hitting $274.58. 58,985 shares of the stock were exchanged, compared to its average volume of 700,582. The company has a market capitalization of $17.13 billion, a P/E ratio of 17.97 and a beta of 0.40. The company has a quick ratio of 2.29, a current ratio of 2.89 and a debt-to-equity ratio of 0.25. The company's 50 day moving average is $242.67 and its two-hundred day moving average is $239.83. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 32.47%. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.
Insider Activity at Ascendis Pharma A/S
In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company's stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 40.00% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Ascendis Pharma A/S
A number of hedge funds have recently modified their holdings of ASND. Chicago Partners Investment Group LLC grew its stake in shares of Ascendis Pharma A/S by 2.3% in the third quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company's stock valued at $564,000 after buying an additional 52 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company's stock worth $62,000 after acquiring an additional 69 shares in the last quarter. Fifth Third Bancorp raised its position in Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 91 shares in the last quarter. ProShare Advisors LLC raised its position in Ascendis Pharma A/S by 5.6% during the third quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company's stock worth $486,000 after acquiring an additional 113 shares in the last quarter. Finally, AlphaCentric Advisors LLC raised its position in Ascendis Pharma A/S by 2.6% during the third quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company's stock worth $1,072,000 after acquiring an additional 121 shares in the last quarter.
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.